Curtis Ruegg, EVP R&D and Technology Operations at Revance Therapeutics, Inc. (RVNC), sold 500 shares at $18.00 ($9K) on 2014-12-09, disclosed to the SEC on 2014-12-11.
Scheduled sale ($9k) by EVP R&D and Technology Operations under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RVNC | SELL | 2016-04-13 | $19K | — | Filing → |
| RVNC | SELL | 2016-03-09 | $20K | — | Filing → |
| RVNC | SELL | 2016-02-10 | $18K | — | Filing → |